Gilead Sciences Inc’s remdesivir had no substantial effect on COVID-19 patients’ chances of survival, a clinical trial by the World Health Organization (WHO) has found, the Financial Times reported.
The results are from WHO’s Solidarity trial, which evaluated the effects of four potential drug regimens in 11,266 hospitalized patients.
The other trials continued in more than 500 hospitals and 30 countries, WHO chief scientist Soumya Swaminathan said.
The study found none of the treatments “substantially affected mortality” or reduced the need to ventilate patients, according to the FT.
The WHO did not comment on the FT report.